IL6 and obesity disorder: A recent prospective observational study from the Nordic Rheumatic Diseases Strategy Trials and Registries showed that obesity was associated to a reduced effectiveness of treatments for RA, including biologic DMARDs such as selective T‐cell co‐stimulation modulators and IL‐6 inhibitors [53].